Who Owns Royalty Pharma Company?

Who Owns Royalty Pharma?

Understanding Royalty Pharma's ownership is key to grasping its strategy and governance. A significant moment was its June 2020 IPO, raising $2.2 billion and becoming the largest U.S. IPO that year.

Founded in 1996 by Pablo Legorreta, the company leads in royalty funding for life sciences. It acquires royalty interests in biopharmaceutical products, offering capital to developers while earning from product sales.

Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, holding interests in over 35 commercial products and 14 development-stage candidates as of February 2024. Its portfolio covers oncology, neurology, infectious diseases, and rare diseases. This analysis explores its ownership changes, including the founder's stake, institutional investors, public shareholders, and shifts over time, offering a complete picture of who owns Royalty Pharma and its Royalty Pharma BCG Matrix.

Royalty Pharma was established in 1996 by Pablo Legorreta, a former investment banker. Legorreta's vision for the company stemmed from observing investment opportunities in drug royalties. He co-founded the company with Rory Riggs, also a former banker.

Founding Vision

Pablo Legorreta identified the potential in drug royalties after a notable investment in a chemotherapy drug. This insight led to the creation of a business model focused on acquiring royalty streams.

Initial Capitalization

In 1996, Legorreta and Rory Riggs successfully raised $60 million to launch the company. This initial funding was crucial for establishing its operations and early investment strategy.

Early Business Model

Royalty Pharma began as a private equity vehicle, concentrating on acquiring royalty rights from approved or late-stage drugs. This approach minimized the risks associated with drug development.

Key Early Stakeholders

The billionaire Giuliani brothers, Germano and Giammaria, became significant early investors after meeting with Legorreta in 1996. Their involvement provided substantial backing during the company's formative years.

Management Structure

Prior to 2024, Pablo Legorreta held sole ownership of RP Management, the external investment manager for Royalty Pharma's assets. This structure underscored his central role in the company's direction.

Funding Sources

The company's initial funding was primarily sourced from private investors. While specific equity splits are not detailed, the capital raised by Legorreta and Riggs was foundational.

The early ownership structure of Royalty Pharma was characterized by private funding and a concentrated management approach. Pablo Legorreta's vision was central to its inception, with significant early backing from individuals like the Giuliani brothers. This foundation allowed the company to pursue its strategy of acquiring drug royalties, a key element in understanding Target Market of Royalty Pharma and its subsequent growth as a public company.

Founders and Early Ownership Dynamics

Royalty Pharma's inception in 1996 was driven by Pablo Legorreta's strategic insight into the drug royalty market. The company's initial funding of $60 million was secured through private channels, with key early investors including the Giuliani brothers.

• Founded in 1996 by Pablo Legorreta and Rory Riggs.
• Initial capital raised was $60 million.
• Focused on acquiring royalty streams from approved or late-stage drugs.
• The Giuliani brothers were major early stakeholders.
• Pablo Legorreta was the sole owner of the external investment manager, RP Management, until 2024.

Complete Royalty Pharma Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Royalty Pharma's ownership landscape transformed significantly with its Initial Public Offering (IPO) on June 16, 2020. This event marked its debut on the Nasdaq Global Select Market, allowing public access to its Class A ordinary shares under the ticker 'RPRX.' The IPO successfully raised approximately $2.2 billion, with shares initially priced at $28.00.

As of March 31, 2025, institutional investors collectively held a substantial 76.82% of Royalty Pharma's outstanding shares, representing 370,363,946 shares distributed among 884 institutional owners. This broad institutional backing underscores the company's appeal to professional investment management. Key shareholders include prominent entities such as Morgan Stanley, Fmr Llc, Vanguard Group Inc, BlackRock, Inc., Baillie Gifford & Co, Swedbank AB, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Viking Global Investors Lp, State Street Corp, and Geode Capital Management, Llc. For instance, Viking Global Investors Lp held 10,563,939 shares, State Street Corp held 9,516,128 shares, and Geode Capital Management, Llc held 7,999,468 shares as of the same date. Understanding who owns Royalty Pharma provides insight into the company's strategic direction and governance. The Brief History of Royalty Pharma details its journey to becoming a publicly traded company.

Royalty Pharma's Dual-Class Share Structure

Royalty Pharma employs a dual-class share structure to manage voting rights and maintain a degree of control for its original investors.

• The company has two classes of voting shares: Class A and Class B ordinary shares.
• Each share class carries one vote per share and votes together on most matters.
• Class B ordinary shares are not publicly traded.
• These Class B shares are primarily held by RPI US Partners 2019, LP and RPI International Holdings 2019, LP.
• Investors in these partnerships can exchange their indirect Class B interest for direct Class A shares.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Royalty Pharma's Board of Directors is led by its founder and CEO, Pablo Legorreta. As of July 2025, the board has significantly enhanced its independent oversight, with over 90% of its members now being independent directors, including recent appointees Carole Ho and Elizabeth (Bess) Weatherman. This composition reflects a commitment to robust corporate governance.

The voting power at Royalty Pharma is structured around a one-share-one-vote principle for both its Class A and Class B ordinary shares. These share classes vote collectively on all shareholder matters, unless legally mandated otherwise. The Class B shares are not publicly traded and are held by specific partnerships, with the option for investors to convert them into Class A shares. This structure means that substantial influence can be wielded by holders of large blocks of either share class. A significant governance enhancement occurred in May 2025 when shareholders overwhelmingly approved, with 99.9% of votes cast, the internalization of its external manager, RP Management, LLC. This strategic move simplifies the corporate structure by bringing all former management employees under direct employment and eliminating external management fees, thereby better aligning leadership with shareholder interests and strengthening the overall governance framework.

Understanding Royalty Pharma's Governance

Royalty Pharma's governance structure is designed to ensure effective oversight and alignment with shareholder interests. The board composition and voting rights are key elements in this framework.

• Founder and CEO Pablo Legorreta leads the Board of Directors.
• Over 90% independent representation on the Board as of July 2025.
• A one-share-one-vote system for Class A and Class B ordinary shares.
• Recent internalization of RP Management, LLC approved by 99.9% of shareholders.
• This internalization simplifies structure and aligns management with shareholders.

Royalty Pharma Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent strategic moves have significantly altered Royalty Pharma's ownership landscape. The company's transition from an externally managed entity to an internally managed one in Q2 2025 marks a pivotal moment, aiming for substantial cost savings and a streamlined corporate structure. This shift, coupled with a large share repurchase program, underscores a focus on shareholder value and internal operational efficiency.

The internalization of its management, approved by approximately 99.9% of shareholders in May 2025, means that all former employees of RP Management, LLC are now direct employees of Royalty Pharma. This move is expected to yield significant financial benefits, with projections of over $100 million in cash savings for 2026 and more than $1.6 billion over the next ten years by eliminating external management fees. Prior to 2024, Pablo Legorreta was the sole owner of the Manager; however, in early 2024, equity interests were granted to 35 team members, vesting over 10 years, to bolster succession planning and team alignment.

Internalization of Management

Royalty Pharma acquired its external manager in Q2 2025. This strategic move is anticipated to generate substantial cost savings, exceeding $100 million in 2026.

Shareholder Returns and Capital Deployment

A $3 billion share repurchase program was authorized in January 2025. The company deployed $2.8 billion in 2024 for new royalty acquisitions, demonstrating a commitment to growth and shareholder value.

Portfolio Performance and Outlook

Portfolio receipts reached $2.8 billion in 2024, with royalty receipts growing by 13%. For 2025, portfolio receipts are projected between $2.9 billion and $3.05 billion.

Strategic Acquisitions and Collaborations

The company continues to acquire royalties, including a synthetic royalty on Rytelo for $125 million in November 2024. This aligns with their Growth Strategy of Royalty Pharma, focusing on development-stage products and strategic funding.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE